News

Unlike other screenings, lung cancer screening is new and patients need to know what happens next, according to Dr. Panagis Galiatsatos.

Pregnancy and delivery are risky times for both mother and child for a number of reasons, but do you know by how much rheumatoid arthritis can increase those risks? Test your knowledge with this quiz.

Buprenorphine is available either in a weekly injection formulation and a monthly formulation for patients already being treated with buprenorphine.

A new analysis found differences in the gut bacteria seen in adults with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity may begin in early childhood.

Dr. Rutland emphasizes the importance of understanding cellular communication and its potential to manipulate disease processes for patient benefit, including the observed link between ILD, inflammation, scarring, and pulmonary hypertension.

In this interview, Marinkovich discussed the implications of the FDA’s landmark approval of B-VEC topical gene therapy for patients with the “butterfly disease.”

The interrupted time-series resulted in an increase in C. difficile infection incidences during the pre-pandemic period from 0.00 to 3.36 infections per 10,000 bed days during the COVID-19 pandemic.

An analysis of cost-effectiveness using data from SOLOIST-WHF provides insight into the varying cost-effectiveness of the agent as a treatment for worsening heart failure.

The approval was based on data from a pharmacodynamic study which showed nalmefene provided a fast onset of reversal of respiratory depression from the synthetic opioid remifentanil.

Promising results from the ATS Conference suggest that AD109, an oral treatment for obstructive sleep apnea, demonstrated significant reduction of AHI and potential mitigation of daytime fatigue.

RBX2660 showed similar efficacy and safety in treating patients with and without immunocompromised conditions.

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

More data is needed to determine whether low-dose levodopa use reduces conversion to neovascular AMD.

Modified production of abicipar was linked to a moderately lower incidence and severity of IOI in nAMD eyes compared with Phase 3 results, but further reductions in IOI are required to match the incidence rates of other anti-VEGF therapies.

In this interview, Stucky discussed his team’s research into an uptick in oral minoxidil prescribing rates for hair loss that had immediately followed the publication of a New York Times article.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

Muthiah Vaduganathan, MD, MPH, offers perspective on data from the PARAGLIDE-HF trial as well as a pooled analysis of data from the PARAGLIDE-HF and PARAGON-HF trials.

There is no additional risk of developing new cancers for patients treated with IBD medications.

According to a release from Oculis, the trial met its stage 1 objective of validating the dosing regimen designed to optimize the efficacy potential of OCS-01 with statistical significance.

The US Food and Drug Administration (FDA) has approved the adalimumab-adbm (Cyltezo) autoinjector pen ahead of the July 1 commercial launch.

Presented at ESC HFA 2023, results of PARAGLIDE-HF detail the effects of sacubitril/valsartan on NT-proBNP and multiple clinical outcomes, relative to valsartan alone, in patients with HFmrEF or HFpEF.

Friedman spoke in this interview segment on improvements that have been made and improvements that he believes are needed to affect change regarding atopic dermatitis treatment disparities.

An analysis of the COPDGene Study presented at ATS 2023 suggests presence of mucus plugs in medium- to large-sized airways were associated with an increased risk of mortality in adjusted models.

AD109 shows the potential to address an unmet need in obstructive sleep apnea treatment.

RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.

However, trends in the incidence of eye injuries associated with non-powder guns should be interpreted with caution as COVID-19 may have interfered with epidemiological trends.

During this interview segment, Friedman further explored the topics in his presentation on fixing disparities in care for eczema patients through teledermatology.

The June 22, 2023 PDUFA date for obeticholic acid 25 mg oral tablets for the treatment of precirrhotic liver fibrosis appears to be in jeopardy after a May 23, 2023 meeting of the FDA's Gastrointestinal Drugs Advisory Committee.